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Background and Aims: The aim of this study was to
determine whether expression of hepatitis C virus pro-
teins alters hepatic morphology or function in the ab-
sence of inflammation. Methods: Transgenic C57BL/6
mice with liver-specific expression of RNA encoding the
complete viral polyprotein (FL-N transgene) or viral struc-
tural proteins (S-N transgene) were compared with non-
transgenic littermates for altered liver morphology and
function. Results: FL-N transcripts were detectable only
by reverse-transcription polymerase chain reaction, and
S-N transcripts were identified in Northern blots. The
abundance of viral proteins was sufficient for detection
only in S-N transgenic animals. There was no inflamma-
tion in transgenic livers, but mice expressing either
transgene developed age-related hepatic steatosis that
was more severe in males. Apoptotic or proliferating
hepatocytes were not significantly increased. Hepatocel-
lular adenoma or carcinoma developed in older male
animals expressing either transgene, but their incidence
reached statistical significance only in FL-N animals.
Neither was ever observed in age-matched nontrans-
genic mice. Conclusions: Constitutive expression of viral
proteins leads to common pathologic features of hepa-
titis C in the absence of specific anti-viral immune re-
sponses. Expression of the structural proteins enhances
a low background of steatosis in C57BL/6 mice, while
additional low level expression of nonstructural proteins
increases the risk of cancer.
Hepatitis C virus (HCV), a positive-strand RNAvirus classified within the family Flaviviridae, is
uniquely capable of establishing persistent infections
within the human liver. Chronic infection results in
necroinflammatory liver disease characterized by the in-
sidious progression of hepatic fibrosis and loss of func-
tioning hepatocyte mass.1–4 A significant proportion of
infected persons ultimately develop cirrhosis, hepatic
failure, and/or hepatocellular carcinoma (HCC).5–7 These
lethal manifestations of hepatitis C result in approxi-
mately 8000–10,000 deaths annually among the 3.9
million Americans infected with this virus.8 Hepatitis C
is thus the single most common cause of clinically sig-
nificant liver disease in the United States today and a
major worldwide threat to public health. However, avail-
able therapies are expensive, difficult to administer, rel-
atively toxic, and effective in a minority of patients.9,10
A better understanding of the mechanisms underlying
the pathology of chronic hepatitis C would be helpful in
designing new strategies for intervening in this disease.
However, research efforts have been hampered by the
lack of both a cell culture system that is permissive for
efficient HCV replication and small animal models that
either support replication of HCV or mimic the patho-
logic features of chronic hepatitis C in humans.11 Little is
known about the molecular mechanisms underlying the
liver injury associated with this viral infection, but a
cell-mediated immune response with prominent lym-
phocytic infiltration of the liver is thought to play a
major role in pathogenesis.12,13 Like other hepatitis viruses,
HCV may replicate in hepatocytes without inducing sig-
nificant cytopathology, and inflammation associated with
the immune response to the infection could account for
most if not all of its pathologic consequences.13,14
However, 2 important observations suggest that non-
immune mechanisms also play an important role in
pathogenesis. These include the frequent presence of
steatosis in chronic hepatitis C, reflecting a metabolic
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abnormality that is not observed as often in other in-
flammatory conditions, such as autoimmune hepatitis or
chronic hepatitis B.15–19 Some lines of evidence also
suggest a distinctive synergy between the liver injury
associated with chronic HCV infection and that accom-
panying alcohol ingestion.20,21 This suggests that HCV
infection uniquely exacerbates alcohol-related metabolic
disturbances.
In addition to these clinical observations, a consider-
able number of in vitro studies have suggested that the
expression of various HCV proteins in cultured cells may
lead to altered lipid metabolism and transport, dysregu-
lation of the cell cycle, either increased or decreased
susceptibility to apoptosis, and cellular transforma-
tion.22–27 However, few data convincingly support a role
for any of these effects in human disease. In part, this
absence of data stems from the lack of suitable animal
models. The chimpanzee (Pan troglodytes) is the only
animal species that is clearly permissive for HCV infec-
tion.28,29 However, unlike humans, infected chimpanzees
typically develop minimal liver disease as a result of viral
replication.
Given the absence of alternative small animal models,
transgenic mice represent a potentially useful model for
determining the long-term consequences of HCV pro-
tein expression in vivo. Here, we describe in detail 2
transgenic mouse lineages that express HCV proteins
under control of the liver-specific murine albumin pro-
moter/enhancer.30 Because mice can be expected to be
immunologically tolerant to transgenic proteins that are
transcriptionally regulated by this promoter, this exper-
imental strategy offers the advantage of providing infor-
mation on the direct, physiologic impact of HCV protein
expression in the absence of confounding factors associ-
ated with immunologic responses to the viral proteins.
The transgenic animals described in this report express
RNAs encoding either the full-length HCV polyprotein
or the structural proteins of a genotype 1b HCV,31,32
including the core, and the E1 and E2-p7 envelope
proteins. The phenotypes of these transgenic lineages
provide strong evidence for nonimmune mechanisms of
liver injury in chronic hepatitis C and suggest an impor-
tant role for the nonstructural proteins of HCC in hep-
atocellular carcinogenesis.
Materials and Methods
Production of Transgenic Mice
The plasmid pGEMAlbSVPA-B1(2) contains the mu-
rine albumin enhancer/promoter30 with a downstream SV40
intron/polyadenylation cassette. Complementary DNA (cDNA)
corresponding to the full-length polyprotein-coding region
(core to NS5B, nts 342–9378) or the structural protein-coding
region only (core to E2/p7, nts 342–2771) of the genotype 1b,
HCV-N strain of HCV31,32 was inserted into this vector be-
tween newly engineered XhoI sites flanking the albumin
enhancer/promoter and SV40 sequence, creating pAlbSVPA-
HCV and pAlbSVPA-HCV-S, respectively. Purified plasmid
DNA (transcriptional units only) was injected into the eggs of
F2 hybrid zygotes generated from mating F1 hybrid male and
female mice (C3H/HeJ 3 C57BL/6). Offspring were screened
for the presence of the transgene by Southern analysis of DNA
extracted from tail biopsies after digestion with HindIII. DNA
from 15 of 55 potential founder (F0) animals obtained after
injection of the full-length FL-N construct (pAlbSVPA-HCV),
and 12 of 38 potential F0 animals obtained after injection of
the structural protein construct S-N (pAlbSVPA-HCV-S) con-
tained the cognate transgene.
Transgenic F0 founder animals were mated with normal
C57BL/6 mice to produce F1 and subsequent generations of
animals. Mice were housed in a controlled, specific, pathogen-
free environment, 4 per microfiltered cage, except when ani-
mals were mating. Animals were fed regular sterile mouse
chow and water. All procedures involving animals were ap-
proved by the Institutional Animal Care and Use Committee.
The preliminary pathologic findings (steatosis and HCC) in
one of these transgenic lineages (FL-N/35) have been reported
elsewhere,33 but a detailed comparison of the frequency of
these findings in transgenic and nontransgenic animals has not
been published.
Transgene mRNA Detection
Total RNA was extracted from approximately 100 mg
of liver tissue pulverized in liquid nitrogen using a phenol-free
total RNA isolation method (RNAqueous; Ambion, Austin,
TX). For Northern blots, total RNA was fractionated in an
agarose gel and passively transferred onto positively charged
nylon membranes (BrightStar; Ambion) following the North-
ern MAX (Ambion) protocol. RNA was cross-linked to the
membranes by ultraviolet (UV) irradiation at 254 nm (UV
Stratalinker; Stratagene, La Jolla, CA). Hybridization of pso-
ralen-biotin–conjugated DNA probes complementary to nts
407–860 of HCV-N and subsequent visualization of the blot
with a streptavidin–alkaline phosphatase conjugate were car-
ried out according to the BrightStar Biodetect Nonisotopic
Detection Kit protocol (Ambion). After washing, membranes
were incubated with CDP-Star chemiluminescent substrate
(Ambion) and exposed to film.
For reverse-transcription polymerase chain reaction (RT-
PCR), total RNA was purified by 2 cycles of RQ1 DNase
digestion, each followed by LiCl precipitation of RNA. Nine
sets of oligonucleotide primers were used to amplify segments
of the HCV genome spanning the entire open reading frame.
RT was carried out with MMLV reverse transcriptase using a
single-tube, 2-compartment RT-PCR procedure (Clontech,
Palo Alto, CA).34 Parallel PCR reactions were performed with-
out a prior RT step to confirm that the template for PCR
amplification products was RNA. PCR products were sepa-
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rated in agarose gels and passively transferred to BrightStar
nylon membranes before hybridization to HCV-specific DNA
probes.
Necropsy and Histopathology Procedures
Animals were killed by CO2 asphyxiation, and liver
tissue was immediately snap-frozen in liquid nitrogen for
RNA isolation and placed in 10% formalin or OCT cryostat
embedding compound (Tissue-Tek, Torrance, CA) for histo-
logic analyses or stored in 5 mmol/L butylated hydroxytoluene
(BHT) for lipid peroxide determinations. Venous blood was
stored frozen for subsequent automated alanine aminotransfer-
ase (ALT) measurements.
H&E- and trichrome-stained, paraffin-embedded liver sec-
tions were examined by a pathologist (S.-Y.X.) who was
blinded to the status of the animal. The degree of steatosis was
estimated from digitized images of frozen liver sections stained
with oil red O. These images were acquired with a Nikon
Diaphot inverted microscope using a blue filter to enhance
contrast and an 8-bit CCD camera (Hamamatsu Instruments,
Japan). The percentage of the area occupied by oil red O–
stained lipid droplets was calculated using Image-1 software
(Universal Imaging Co., West Chester, PA), averaging 3–5
separate, randomly selected 403 fields.
Immunohistochemical Detection of
Viral Antigen
HCV core protein was detected by immunohistochem-
ical analysis of formalin-fixed transgenic liver tissue sections.
Endogenous peroxidase activity was blocked by immersing
sections in 3% H2O2 in phosphate-buffered saline with 0.1%
Tween 20 for 15 minutes, followed by antigen retrieval with
0.3% pepsin in 0.01 mol/L HCl at 37°C for 15 minutes. A
murine monoclonal antibody to the HCV capsid protein,
27D5G5 (generously provided by G. Inchauspe´ of INSERM
Unite 271, Lyon, France) was used as the primary antibody at
a dilution of 1:100, followed by incubation with a biotinylated
goat anti-mouse immunoglobulin as the secondary antibody
(Dako, Carpinteria, CA). Slides were incubated with strepta-
vidin–horseradish peroxidase conjugate, followed by 3-amino-
9-ethylcarbazole as substrate (Dako), and counterstained with
hematoxylin before mounting.
For detection of the E2 protein, frozen sections of the liver
were fixed in acetone, blocked with normal goat serum and
avidin/biotin (Avidin/Biotin Blocking kit; Vector Laborato-
ries, Burlingame, CA), and incubated at 4°C overnight with a
1:500 dilution of a rabbit antibody raised to a peptide identical
in sequence to the hypervariable region 1 of the E2 protein of
HCV-N (S. M. Lemon, unpublished observations, January,
1997). Specificity was confirmed by the parallel staining of
tissues with a rabbit antibody specific for a salivary protein of
the sand fly, Lutzomyia longipalpis. Endogenous peroxidase ac-
tivity was depleted with 1% H2O2 and 0.1% sodium azide,
and sections were incubated with biotinylated goat anti-rabbit
immunoglobulin (Ig) G (1:200) at room temperature for 2
hours. Following incubation with avidin-conjugated peroxi-
dase (Vectastain Elite ABC; Vector Laboratories), and develop-
ment in 3,39-diaminobenzidine tetrahydrochloride (DAB) with
0.1% H2O2, nuclei were counterstained with hematoxylin.
Apoptosis Assay
In situ detection of DNA fragmentation was carried
out using a fluorescence-based assay (Fluorescein-FragEL, On-
cogene Research Products, Boston, MA). Frozen liver sections
(5 mm) were fixed in 4% formaldehyde and rehydrated in 20
mmol/L Tris-HCL, pH 7.6, 140 mmol/L NaCl. Sections were
digested with proteinase K (20 mg/mL) for 10 minutes and
incubated with terminal deoxynucleotide transferase and flu-
orescein-labeled nucleoside triphosphates at 37°C for 90 min-
utes, then washed in buffer and placed under coverslips in
mounting fluid containing 4,6-diamidino-2-phenylindole
(DAPI) for counterstaining of nuclei. Slides were examined at
an excitation wavelength of 465–495 or 330–380 nmol/L.
Numbers of apoptotic nuclei were counted in each of 10
randomly selected 403 fields.
Immunocytochemical Detection of
Proliferating Hepatocytes
5-Bromo-29-deoxyuridine (BrdU) was administered to
mice by intraperitoneal injection (100 mg/kg) 5 hours before
necropsy. The liver and small intestines (the latter included as
a positive control containing S-phase epithelial cells) were
removed at necropsy and fixed in 10% neutral buffered for-
malin for paraffin embedding and preparation of sections.
Endogenous peroxidase activity was blocked by immersing
sections in 0.3% H2O2 in methanol for 30 minutes, followed
by digestion with 0.05% pepsin in 0.01N HCl. After incu-
bation in 2N HCl for 30 minutes at 37°C, slides were washed
for 10 minutes in 0.1 mol/L borax buffer (pH 8.5) and murine
monoclonal anti-BrdU IgG (Becton Dickinson, Franklin
Lakes, NJ) applied at a 1:500 dilution overnight at 4°C. After
further washing, slides were incubated with a biotinylated
F(ab9)2 fragment of sheep anti-mouse IgG (1:100 dilution) for
1 hour, followed by DAB as chromagen. Sections were scored
for the number of cells incorporating BrdU as described for
apoptosis.
Intrahepatic Lipid Peroxides
Malonaldehyde and 4-hydroxynonenal concentrations
were determined in liver tissue homogenates by a colorimetric
assay (LPO-586; OXIS International, Portland, OR). The pro-
tein content of the homogenates was determined using a
Coomassie blue assay (Pierce, Rockford, IL).
Results
Transgene Expression in FL-N and S-N
Transgenic Mice
Transgenic mice were designed to express either
the full-length HCV-N open reading frame (FL-N) or
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the segment encoding the structural proteins only (S-N:
core and the 2 envelope proteins, E1 and E2-p7; Figure
1). F1 offspring bred from 15 potential FL-N founder
animals and 12 potential S-N founder animals were
evaluated for mRNA transcription at 2 months of age.
Intrahepatic RNA transcripts were not present in an
amount detectable by Northern analysis in any of the F1
animals harboring the FL-N transgene (Figure 2A ). In
contrast, HCV-specific mRNA was readily detected by
Northern analysis of RNA extracted from the liver of
animals in 2 of the 12 S-N transgenic lineages (S-N/857
and S-N/863; Figure 2B). In both of these lineages, the
Figure 1. Hepatitis C transgene organization. (A) The HCV open reading frame within the FL-N transgene encodes the entire polyprotein of a
genotype 1b strain of HCV. (B) The S-N transgene encodes the amino third of the polyprotein and thus expresses only the structural proteins core,
E1, and E2p7. In each transgene, the HCV open reading frame is under the transcriptional control of the murine albumin promoter/enhancer,
and upstream of an SV40 intron/poly(A) addition signal
Figure 2. Detection of transgene-specific RNA in transgenic mice by DNA hybridization. (A) No HCV-specific transcripts were detected by Northern
analysis of RNA extracted from the livers of animals bearing the FL-N transgene. Shown are results with RNAs extracted from normal liver (N) or
tumors (T) in 2 transgenic animals from the FL-N/35 lineage (animals 170 and 171, lanes 4–7 ). Positive controls included synthetic
genome-length RNA (FL, lane 1) and RNA transcripts representing the structural region of the genome only (S, lane 2). Lane 3 contains normal
C57BL/6 mouse RNA. The blot was hybridized with a mixture of DNA probes specific for HCV and mouse actin. (B) Northern detection of ;2.5-kb
HCV-specific transcripts in RNA extracted from livers of mice in the S-N/857 and S-N/863 lineages. Gels were loaded with 20 mg of total RNA
purified from mouse liver (lanes 4–6 ), 0.2 mg of mRNA isolated from the stably transformed cell line CHO-C2A8 that expresses a message
identical to the S-N transgene (lane 3) or an equivalent amount of normal mouse RNA (lane 4). A total of 50 pg (lane 1) or 5 pg (lane 2) of 9.5-kb
synthetic RNA was mixed with 20 mg of normal mouse liver RNA and electrophoresed in parallel as an additional positive control. Hybridization
was with a mixture of DNA probes targeting the core sequence.
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dominant RNA band was of the expected length (;2.5
kb), and identical in size to transcripts present in a stable
transformed cell line expressing the identical HCV se-
quence (CHO-C2A8 cells).26 Thus, there was no signif-
icant splicing of transcripts expressed from the S-N
transgene.
Although Northern analyses of the FL-N lineages did
not show HCV-specific RNAs, transcription of the trans-
gene was confirmed in 4 of these lineages by RT-PCR
using primers designed to amplify the core-E1 region
(Table 1). To determine whether a full-length transcript
was produced, 9 separate PCR reactions were carried out
using primer sets designed to span the entire HCV
polyprotein-coding region and template cDNA produced
by RT of RNA from animals in the FL-N/35 lineage
(Figure 3). A specific amplification product of the ex-
pected size was generated in each reaction, but only after
RT of the RNA. Although these results do not exclude
the possibility that a proportion of the transcripts are
inappropriately spliced, they provide compelling evi-
dence for the presence of full-length RNA encoding the
entire polyprotein in these animals. In addition to the 2
S-N lineages in which RNA was detectable by Northern
analysis (Figure 2B), liver samples from mice in 3 other
S-N lineages also contained HCV-specific RNA detect-
able by RT-PCR (Table 1).
Table 1. Summary of HCV Transgenic Mouse Lineages
Transgene and
lineage
Transgene mRNA expression
Transgenic animals
evaluated (n)
Observed histopathology
Northern
analysis RT-PCR
Hepatic
steatosisa
Hepatocellular
carcinoma
Full-length ORF
FL-N/35 2 1 73 1 1
FL-N/984 2 1 1 ND 1
FL-N/986 2 1 10 1 2
FL-N/964 2 1 5 ND 2
Structural proteins
S-N/863 1 1 89 1 1
S-N/857 111 1 4 ND 2
S-N/866 2 1 2 ND 1
S-N/883 2 1 1 ND 1
S-N/888 2 1 3 ND 2
aND, not determined, insufficient numbers of animals available.
Figure 3. HCV-specific transcripts span the entire polyprotein-coding region in livers of mice from the FL-N/35 lineage. RT-PCR was carried out
with 9 nested pairs of oligonucleotide primers amplifying genome segments spanning the entire polyprotein-coding region. The template material
was 1 mg of total RNA that had been subjected to 2 cycles of DNAse digestion followed by precipitation with lithium chloride to remove cellular
DNA. A schematic showing the organization of the polyprotein-coding region is shown at the bottom of the figure. Above it are depicted the cDNA
segments amplified by individual primer pairs, the 59 map location of primers (Table 1), and the length of the expected PCR amplimer. Above each
is the result of DNA hybridizations of Southern blots of PCR amplimers obtained with RNA from livers of transgenic (transgene1) or nontransgenic
(transgene2) mice. Reactions were run with (reverse transcriptase1) or without (reverse transcriptase2) a prior RT reaction to show that
HCV-specific sequences were amplified from RNA.
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HCV Protein Expression
We used the core and E2 proteins as markers for
protein expression since both are encoded by the FL-N
and S-N transgenes (Figure 1). The immunohistochem-
ical detection of core protein in formalin-fixed, trans-
genic liver tissue is shown in Figure 4A and B. Cyto-
plasmic staining for core antigen was prominent in
pericentral hepatocytes in liver from the S-N/857 lineage
(Figure 4B). However, the core protein was not expressed
at detectable levels in animals from the S-N/863 lineage,
which showed a lower abundance of S-N transcripts than
the S-N/857 lineage as determined by Northern analysis
(Figure 2B). Similarly, core protein could not be detected
in liver tissues from the FL-N lineages (data not shown)
in which a low abundance of the full-length open reading
frame message was detectable only by RT-PCR (Figures
2A and 3). The presence of a detectable abundance of the
;21-kilodalton core protein in the S-N/857 lineage, and
its absence in the other lineages, was confirmed by
immunoblot analysis of liver tissue homogenates. In
parallel immunoblots of human tissue, the core protein
was detectable in only 1 of 3 patients with chronic
hepatitis C (data not shown).
Detection of the E2 protein proved a more sensitive
indicator of protein expression. This protein was readily
detectable by immunohistochemical techniques when
frozen sections of livers from animals in both the S-N/
857 and S-N/863 lineages were stained with a rabbit
antiserum raised to a synthetic peptide representing the
hypervariable region of the HCV-N E2 protein (Figure
4C and E ). As with core protein in the S-N/857 lineage,
E2 was cytoplasmic in distribution (Figure 4E ) and
particularly prominent in pericentral hepatocytes (Figure
4F ). Parallel staining of these tissues with a rabbit
Figure 4. Immunohistochemical detection of
HCV structural proteins in livers of mice from
S-N and FL-N transgenic lineages. (A, B ) Im-
munoperoxidase detection of HCV core pro-
tein in formalin-fixed sections of mouse liver
stained with a murine monoclonal antibody
to the HCV core protein. (A) Nontransgenic
mouse liver showing no expression of core
protein (203 objective); (B) liver from a trans-
genic animal in the S-N/857 lineage, show-
ing pericentral distribution of cytoplasmic
staining for core antigen in hepatocytes (203
objective). (C–F ). Detection of E2 protein in
liver of transgenic mice. Liver samples were
cryosectioned and stained with a rabbit anti-
body specific for the E2 protein of HCV-N,
followed by a biotinylated secondary anti-
body and avidin-conjugated peroxidase. Nu-
clei were counterstained with Gill hematoxy-
lin. (C) Nontransgenic mouse liver (403
objective); (D) transgenic liver from the FL-
N/35 lineage (403 objective); (E) transgenic
liver from the S-N/863 lineage (403 objec-
tive); (F ) low power view of transgenic liver
from the S-N/863 lineage (103 objective)
showing pericentral distribution of the cyto-
plasmic E2 antigen. Parallel staining using
rabbit antibody specific for an irrelevant anti-
gen (a peptide derived from a salivary protein
of sand fly Lutzomyia longipalpis) showed no
positively stained cells in the livers of non-
transgenic and transgenic mice (data not
shown).
February 2002 LIVER INJURY IN HEPATITIS C TRANSGENIC MICE 357
antibody specific for an irrelevant antigen (a peptide
derived from a salivary protein of the sand fly Lutzomyia
longipalpis) revealed no positively stained cells in the
livers of either nontransgenic or transgenic mice (data
not shown), confirming the specificity of the antigen
detection in the S-N/857 and S-N/863 tissues. In con-
trast, although faint staining may have been present,
liver sections from animals in the FL-N/35 lineage did
not contain clearly demonstrable amounts of E2 protein
(Figure 4D). Similar results were obtained with indirect
immunofluorescence staining of tissue sections (data not
shown). Overall, there was good correlation between
transgene mRNA expression levels and the detection of
viral proteins (Table 2).
Phenotypes of FL-N and S-N
Transgenic Mice
Of the 9 transgenic lineages with evidence of
RNA transcription listed in Table 1, only 2 proved
capable of breeding in large numbers (FL-N/35 and
S-N/863). The frequency of transmission of the transgene
to F1 and F2 offspring in both lineages approximated
50%, consistent with the results of Southern analysis of
tail biopsy DNA, which suggested a single, unique site
of transgene integration in each (data not shown).
In general, the transgenic mice appeared normal and
did not have demonstrable deficits in growth or devel-
opment. No cellular inflammatory infiltrate was evident
in the livers of these mice, and there were no significant
differences in the serum ALT activities of transgenic
animals and their nontransgenic littermates (data not
shown). However, hepatic steatosis was frequently
present in older transgenic animals from the FL-N/35,
FL-N/963, and S-N/863 lineages, and transgenic animals
in the FL-N/35 and S-N/863 lineages developed HCC.
Similar pathology, including HCC, was present in trans-
genic animals from other lineages, but the frequency of
liver disease in these lineages could not be determined
because of the limited numbers of animals available
(Table 1).
Hepatic Steatosis
In contrast to a modest degree of steatosis noted
occasionally in normal aging C57BL/6 mice, a substan-
tial proportion of transgenic mice from the FL-N/35 and
S-N/863 lineages developed moderate to severe steatosis
(Figure 5A and B). This was characterized by a typical
vacuolated appearance of lipid-laden hepatocytes in
H&E-stained sections of the liver (Figure 5C ), and con-
firmed by the demonstration of increased intrahepatic
lipid on oil red O staining of frozen sections (Figure 5D).
Steatosis was primarily centrilobular (Figure 5B), and
either microvesicular or mixed microvesicular/macro-
vesicular (Figure 5C ).
Steatosis increased with age in the transgenic animals
and was rare before age 10 months in either lineage.
Digitized images of oil red O–stained liver sections were
analyzed to quantify the degree of steatosis, with the
percent area occupied by oil red O–stained fat droplets
estimated in individual liver sections. The area occupied
with fat was significantly greater in FL-N/35 transgenic
animals 9–15 months of age than in age-matched, non-
transgenic mice (P , 0.02 by Student t test; Figure 5E ).
Steatosis was significantly more prominent in transgenic
males (19.3% 6 4.4% SEM) than females (8.4% 6
1.1%; P , 0.05). A comparable degree of steatosis was
documented in a small number of similarly aged trans-
genic animals from a second, independent FL-N lineage,
FL-N/986, and in 12–16-month-old transgenic animals
from the S-N/863 lineage (Figure 5E ). In the latter
lineage, the area occupied by oil red O–stained lipid
droplets in transgenic animals significantly exceeded that
in sections from age-matched, nontransgenic littermates
(P , 0.02). Although modest staining with oil red O
was occasionally present in nontransgenic male mice
(6.9% 6 2.3%), it occupied relatively little of the overall
area of the sections from nontransgenic females (3.5% 6
2.8%; P 5 NS). Because Southern blots indicated that
the transgene insertion sites are different in these 3
lineages (data not shown), steatosis did not result from
fortuitous insertional inactivation of a mouse gene. Its
occurrence in the S-N/863 lineage indicates that it can be
Table 2. Summary of Protein Expression Studies in Transgenic Mouse Lineages
Transgene
and lineage
mRNA
expressiona
Core protein E2 protein
Immunohistochemistry Immunoblot Immunohistochemistry Immunofluorescence
FL-N/35 1 2 2 2 2
S-N/863 11 2 2 111 111
S-N/857 111 11 11 111 111
aSee Table 1.
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Figure 5. Hepatic steatosis in FL-N/35 lineage mice. (A) Nontransgenic male, age 12 months, H&E-stained paraffin section showing normal liver
histology (103 objective). (B ) Transgenic male, age 13 months, H&E-stained paraffin section (103 objective). Note marked steatosis present
diffusely in zones 2 and 3. (C) Higher magnification of the pericentral region of the same liver as shown in B (403 objective) showing mixed
macrovesicular and microvesicular characteristics of the steatosis. (D) Transgenic male, age 11 months, oil red O–stained frozen section (103
objective) showing darkly stained lipid droplets in zones 2 and 3. (E) Quantitative analysis of digitized images of oil red O–stained frozen liver
sections. For each liver, the mean percent area occupied by oil red O–stained lipid droplets was calculated for 3–5 randomly selected fields.
Results shown represent the means for transgenic (shaded bars) and nontransgenic (open bars) animals in 3 different lineages: FL-N/35,
FL-N/963 (no nontransgenic animals), and S-N/863. For the FL-N/35 lineage, 15 transgenic animals aged 9–15 months (mean age, 12.1
months; 67% males) were compared with 13 nontransgenic animals of comparable age and sex (mean age, 11.3 months; 69% males) from the
colony (P , 0.05 by 2-sided t test). Results for the FL-N/963 lineage were restricted to 4 transgenic animals, 3 females and 1 male (mean age,
12.3 months). For the S-N/863 lineage, 9 transgenic animals aged 13–16 months (mean age, 14.6 months; 67% males) were compared with
6 comparably aged nontransgenic littermates (mean age, 14.7 months; 100% males; P , 0.02 by t test). Error bars indicate SDs.
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related to the expression of one or more of the structural
proteins.
Although centrilobular microvesicular steatosis can
result from mitochondrial injury and predispose to in-
creased lipid peroxidation,35 there were no significant
differences in the basal level of lipid peroxides in non-
transgenic animals (51.1 6 4.5 SEM pmol/mg protein
over the age of 8 months, n 5 24) and in similarly aged
FL-N/35 transgenic (55.6 6 8.9 pmol/mg, n 5 15) or
S-N/863 transgenic animals (38.9 6 8.9 pmol/mg,
n 5 15).
Hepatic Fibrosis
Fibrosis is a characteristic pathologic feature of
chronic hepatitis C.18,35 However, there was no fibrosis in
these mouse livers in the absence of cancer. HCC tissues
from transgenic animals contained fibrosis evident in
trichrome stains (data not shown), as well as prominent
activation of stellate cells detectable by immunostaining
with a monoclonal antibody specific for a-smooth muscle
actin36 (data not shown). Cells staining specifically for
a-smooth muscle actin were present only occasionally in
non-tumor tissue from these animals, or in transgenic
animals without tumors.
Hepatocellular Proliferation and Apoptosis
Because in vitro studies suggest that HCV pro-
teins may alter cell signaling and regulate apoptotic
pathways,23–26 we compared transgenic mice from both
lineages with their age-matched nontransgenic litter-
mates for evidence of increased or decreased numbers of
apoptotic hepatocytes. No consistent differences were
apparent. We also compared basal hepatocyte prolifera-
tion rates in 9–11-month-old transgenic and nontrans-
genic mice by assessing the frequency of hepatocytes
incorporating BrdU over a 5-hour period before necropsy
(Figure 6). Although the highest numbers of proliferat-
ing cells were observed in transgenic males from the
FL-N/35 lineage (Figure 6A, 3.1 6 1.3 cells per 403
field compared with 0.82 6 0.7 cells in nontransgenic
males from the lineage), this difference did not achieve
statistical significance. Somewhat higher numbers of pro-
liferating cells were also present in transgenic mice com-
pared with nontransgenic mice in the S-N/863 lineage
(Figure 6B), but this difference also did not achieve
statistical significance.
Hepatocellular Carcinogenesis
Hepatic adenomas or HCC ranging from a few
millimeters to more than 2 cm in diameter were present
at necropsy in 5 of 37 FL-N/35 transgenic mice and in 1
of 42 S-N/863 transgenic mice older than 13 months
(Table 3). The morphology of the HCCs was variable,
with some showing well-differentiated hepatic cords
with proliferating hepatocytes and others containing
markedly thickened trabeculae or acini of dysplastic
hepatocytes with prominent sinusoidal spaces (Figure 7).
Multiple tumors were identified in 2 transgenic animals.
One liver with a typical carcinoma contained a separate
mass with morphology consistent with focal nodular
hyperplasia. Focal or diffuse steatosis was sometimes
disproportionately present in the adenomas or HCCs
(Figure 7A and C ), but there was no apparent correlation
between the presence or severity of steatosis and the
occurrence of HCC.
All of the tumors identified in transgenic animals
occurred in males. Adenomas or HCC were present in 5
of 17 male FL-N/35 transgenic mice older than 13
months, a frequency that was significantly greater than
in age-matched female FL-N/35 transgenic animals (0 of
20; P , 0.02 by Fisher exact test) or in nontransgenic
male mice (0 of 24; P , 0.01). In contrast, HCC was
found in only 1 older transgenic male from the S-N/863
lineage (Table 3). The frequency of tumors in older male
S-N/863 transgenic animals (1 of 24) was significantly
less than that in comparably aged males in the FL-N/35
Figure 6. Numbers of hepatocytes showing evidence of DNA synthe-
sis as indicated by BrdU incorporation in 10 randomly selected 403
fields of liver sections from transgenic and nontransgenic animals. (A)
Numbers of hepatocyte nuclei showing BrdU incorporation in 8 FL-
N/35 transgenic animals (mean age, 10.0 months) compared with an
equal number of age-matched nontransgenic littermates (P 5 0.19).
(B) Numbers of hepatocyte nuclei showing BrdU incorporation in 7
S-N/863 transgenic animals (mean age, 10.6 months) compared with
4 nontransgenic littermates (mean age, 10.7 months; P 5 0.12). In
each panel, the mean numbers of positive cells are shown separately
for transgenic (shaded bars) and nontransgenic (open bars) litter-
mates with values shown for individual male (F) and female (E) mice.
Error bars represent SDs.
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lineage (P , 0.05), and not statistically different from
the absence of adenomas or liver cancer in age-matched
nontransgenic males. Because the structural proteins of
HCV were expressed at a higher level in the S-N/863
than the FL-N/35 lineage (Figure 4), the greater fre-
quency of cancer in comparably aged mice in the FL-
N/35 lineage suggests that the nonstructural proteins of
HCV may contribute to hepatic carcinogenesis even
when they are expressed at levels below those detectable
by immunohistochemistry. However, a relatively small
number of S-N/863 animals were available for necropsy
at ages .18 months, and further observation is needed to
determine the risk of cancer in very old mice in this
lineage.
Figure 7. Photomicrographs of liver tumors in HCV-transgenic mice. (A) Small hepatic adenoma, with macrovesicular steatosis at the center, in
a 13-month-old male mouse from the FL-N/35 lineage (103 objective). (B ) HCC in another 13-month-old male from the FL-N/35 lineage. Note
dysplastic hepatocytes forming thickened cellular trabeculae (203 objective). (C) HCC in a third 13-month-old male from the FL-N/35 lineage,
with focal steatosis and cytoplasmic hyaline globules in hepatocytes (203 objective). (D) A well-differentiated HCC in an 18-month-old male from
the S-N/863 lineage (203 objective).
Table 3. Frequency of HCC by Age in Transgenic Lineages
Age (mo)
FL-N/35 S-N/863
All
nontransgenicTransgenic Nontransgenic Transgenic Nontransgenic
0–6 0/6 0/4 0/24 0/15 0/19
7–9 0/8 0/9 0/6 0/6 0/15
10–12 0/21 0/18 0/16 0/10 0/28
13–15 3/20 0/5 0/19 0/25 0/30
16–18 1/13 0/8 0/15 0/7 0/15
.18 1/5 0/3 1/7 0/5 0/8
All ages 5/73 0/47 1/89 0/66 0/115
$13 5/38 0/16 1/43 0/35 0/53
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We examined tumors from the FL-N/35 lineage for
evidence of transgene mRNA and antigen expression and
found results similar to those obtained with normal
transgenic tissue. Specific HCV mRNA was detectable
by RT-PCR, and results of Northern analyses of these
tissues were repeatedly negative (Figure 2). Neither the
core nor the E2 antigens were present in amounts de-
tectable by immunohistochemical techniques.
HCC was not restricted to the FL-N/35 and S-N/863
lineages but also occurred in isolated transgenic animals
from other lineages (Table 1). The morphologies of these
tumors were similar to those described previously, and
all occurred in older male animals (15–17 months old)
from lineages with active transcription of the transgene.
HCC was not observed in mice from transcriptionally
inactive lineages or in nontransgenic animals, including
a total of 115 nontransgenic littermates from the FL-
N/35 and S-N/863 lineages (Table 3). These nontrans-
genic littermates were caged with transgenic animals and
received an identical diet.
Discussion
The HCV-transgenic mice that we have derived
constitutively express low levels of RNA encoding the
complete viral polyprotein, or higher levels of the RNA
segment encoding only the structural proteins of the
virus, under control of a liver-specific promoter. Protein
expression was confirmed directly only in the mice ex-
pressing the structural region of the polyprotein and
was insufficient for detection even with sensitive im-
munohistochemical techniques in mice with the full-
length reading frame as the transgene. Nonetheless, these
FL transgenic animals showed distinctive phenotypes,
strongly suggesting the presence of a biologically rele-
vant level of HCV protein expression. Both types of
transgenic mice showed no evidence of inflammation,
indicating that they do not mount a significant cellular
immune response to expressed viral proteins. Thus, the
pathologic findings in these animals, including steatosis
in mice of the FL-N/35, FL-N/963, and S-N/863 lin-
eages and the development of liver cancer in older male
FL-N/35 mice, arise as a direct result of the expression of
viral proteins. These findings suggest that similar non-
immune mechanisms may contribute to the development
of steatosis and liver cancer in humans with chronic
hepatitis C.
These HCV-transgenic mice are significantly different
from those described previously by others. Although
Moriya et al.37,38 also observed steatosis and HCC in
transgenic mice, these animals expressed only the core
protein, and not the other structural or nonstructural
proteins encoded by the FL-N and S-N transgenes. The
core protein interacts with the envelope proteins39 and
possibly also one or more nonstructural proteins, and
such interactions between viral proteins could signifi-
cantly modulate their effects in vivo. This makes it
important to study the activities of HCV proteins within
the context of the entire viral polyprotein rather than in
isolation. In addition, the mice described by Moriya et
al.37,38 appear to express core protein in relatively large
amounts because it was readily detectable in immuno-
blots. This contrasts with the absence of detectable ex-
pression of HCV proteins in the FL-N/35 lineage and the
fact that RNA transcripts could be detected in this
lineage only by RT-PCR (Figure 3). RT-PCR is rou-
tinely required to detect the low levels of HCV RNA
transcripts in most patients. Furthermore, viral proteins
are not present at amounts detectable in many patients
with chronic HCV infection. Although results have var-
ied in different studies, 25%–75% of patients with
chronic hepatitis C do not have levels of core antigen
detectable in liver tissue even with sensitive assays using
monoclonal antibodies.17,40–42 Thus, not only does the
FL-N/35 lineage express RNA encoding the full com-
plement of HCV proteins, it is also likely to express the
viral proteins at levels mimicking the situation in many
infected humans.
Despite the absence of detectable levels of protein
expression, liver cancer developed as early as 13 months
of age in FL-N/35 mice. In contrast, liver cancers did not
occur until 16 months in the core-transgenic mice de-
scribed by Moriya et al.38 However, steatosis was prom-
inent by age 6 months in the transgenic mice studied by
Moriya et al.37 and was frequently present in females,
whereas steatosis was rarely present before age 10 months
in FL-N/35 animals and was infrequently seen in fe-
males. This latter difference may reflect the higher level
of core protein expression in the mice studied by Moriya
et al., but it also suggests the absence of a direct link
between steatosis and carcinogenesis. It further suggests
that HCV proteins other than core may promote the
development of cancer. This conclusion is reinforced by
the low rate of cancer in 13–18-month-old S-N/863
lineage animals compared with that observed in the
FL-N/35 lineage (Table 1). Dysregulation of cell growth
has been associated with the expression of core in cul-
tured cells,24–26,43 but potential roles in carcinogenesis
have also been suggested for the NS3 and NS5A pro-
teins.27,44 These proteins are encoded by the FL-N/35
transgene, and the higher rate of cancer in this lineage
suggests that even very low-level expression of these
proteins may contribute to hepatocellular carcinogenesis.
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Further observation of the S-N/863 lineage is needed to
determine whether these transgenic mice are at increased
risk for liver cancer at ages greater than 16–18 months.
Both the mice described by Moriya et al.37,38 and those
described here were developed within a predominantly
C57BL/6 genetic background. This may be important to
the disease observed in these animals; 2 other groups of
investigators, Kawamura et al.45 and Pasquinelli et al.,46
found no pathology in transgenic mice expressing the
core protein of HCV in different genetic backgrounds.
Others have noted that normal aging C57BL/6 mice are
at risk for the development of mild steatosis,47 a phe-
nomenon we confirmed in our animals (Figure 5E ). Thus
it is possible that HCV gene expression may act to
exacerbate an underlying metabolic abnormality in
C57BL/6 mice that is not present in other inbred strains
of mice. If genetic background is proven to be an im-
portant factor in determining disease expression in HCV-
transgenic mice, it may provide useful clues to the
mechanisms underlying the variable risk of disease in
persons with chronic HCV infection.
Although it is not clear which HCV protein(s) pro-
mote steatosis in the FL-N/35 mice, its occurrence in the
S-N/863 lineage indicates the involvement of one or
more structural proteins. This is consistent with the
occurrence of steatosis in transgenic animals that express
only high levels of the core protein.38 Core protein
physically associates with cytoplasmic lipid droplets
through an interaction with apolipoprotein A2, and this
may alter normal lipid transport leading to steatosis.22,48
However, steatosis was at least as prominent in the
FL-N/35 lineage as the S-N/863 lineage (Figure 5E ),
despite the absence of a detectable abundance of HCV
structural proteins in the former (Figure 4D). This raises
the possibility that very low-level expression of one of the
nonstructural proteins encoded by the transgene in the
FL-N/35 or FL-N/963 animals may have contributed to
steatosis. NS5A has recently been found to interact with
apolipoprotein A1 and to colocalize with the core protein
on cytoplasmic lipid droplets (Stephanie T. Shi and
Michael M. C. Lai, personal communication, April
2001). Thus it is possible that this interaction further
promotes the accumulation of intracellular lipids in-
duced by core.
Alternatively, core protein is capable of interacting
with the cytoplasmic domain of several members of the
tumor necrosis factor receptor family.25,43 The conse-
quences of this interaction are controversial but could
include constitutive activation of proapoptotic cell sig-
naling, leading to a mitochondrial permeability transi-
tion and subsequent oxidative stress.49,50 However, we
did not find increased rates of hepatocellular apoptosis in
our mice. Yet a third possibility is that the core protein
could interact directly with mitochondria.38 We recently
found that the expression of core protein leads to demon-
strable mitochondrial injury with attendant increases in
the abundance of reactive oxygen species in several types
of cultured cells.51 The centrilobular (zone 3) micro-
vesicular steatosis observed in these mice could reflect
such mitochondrial injury. As reported here, we found no
increases in the basal levels of lipid peroxides in the livers
of mice from either the FL-N/35 or S-N/863 lineages.
However, we have documented elevated levels of intra-
hepatic lipid peroxidation products in transgenic S-N/
863 mice after low-dose carbon tetrachloride exposure.51
These results suggest that these transgenic mice are at
increased risk of tissue damage in the face of oxidative
stress. The accumulation of reactive oxygen species re-
sulting from mitochondrial dysfunction could contribute
to carcinogenesis by promoting chromosomal DNA
damage and altering the regulation of apoptosis.35 In
addition to the core protein,52 the generation of intra-
cellular reactive oxygen species has been linked recently
to expression of the NS5A protein, providing yet another
potential explanation for the increase in hepatic carcino-
genesis we observed with the inclusion of the HCV
nonstructural proteins among those encoded by the
transgene in the FL-N/35 animals.
In addition to these potential nonimmune mecha-
nisms of liver injury, chronic inflammation associated
with the cellular immune response to HCV infection is
likely to play an important role in the development of
HCC in humans. Inflammation would be expected to
exacerbate oxidative stress induced by the expression of
viral proteins in an already vulnerable liver, potentially
accelerating the progression to hepatocellular carcino-
genesis. Nonetheless, the results described here show
that the intrahepatic expression of HCV proteins directly
promotes the development of steatosis and significantly
enhances the risk of liver cancer in the absence of inflam-
mation, and provide novel evidence for the involvement
of the nonstructural proteins of HCV in these pathoge-
netic processes.
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